| TAM (n = 240) | TOR (n = 212) | P value |
---|---|---|---|
Age | Â | Â | 0.552 |
18-34 | 34 | 26 | Â |
>35 | 206 | 186 | Â |
T | Â | Â | 0.744 |
 1 | 147 | 137 |  |
 2 | 84 | 67 |  |
 3 | 9 | 8 |  |
N | Â | Â | 0.536 |
 0 | 142 | 136 |  |
 1-3 | 61 | 52 |  |
 4-9 | 27 | 19 |  |
 ≥10 | 10 | 5 |  |
AJCC Stage | Â | Â | 0.616 |
 I | 98 | 97 |  |
 IIA | 70 | 64 |  |
 IIB | 32 | 25 |  |
 IIIA | 30 | 21 |  |
 IIIB | 0 | 0 |  |
 IIIC | 10 | 5 |  |
HER-2 status | Â | Â | 0.359 |
 Positive | 37 | 23 |  |
 Negative | 148 | 137 |  |
 Unknown | 55 | 52 |  |
Grade | Â | Â | 0.328 |
 I | 51 | 37 |  |
 II | 141 | 120 |  |
 III | 47 | 52 | 0.530 |
 Unknown | 1 | 3 |  |
Risk of recurrence | Â | Â | 0.313 |
 Low | 11 | 15 |  |
 Intermediate or | 229 | 197 |  |
 high |  |  | 0.024 |
Local control | 117 | 130 | Â |
 BCS + RT | 90 | 57 |  |
 Modified | 33 | 25 |  |
 Modified + RT |  |  | 0.513 |
Chemotherapy | 15 | 10 | Â |
 CMF | 96 | 92 |  |
 ET | 62 | 42 |  |
 FEC | 43 | 45 |  |
 TC | 24 | 23 |  |
 No chemotherapy |  |  |  |